569 related articles for article (PubMed ID: 16027121)
1. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity.
Hahn-Windgassen A; Nogueira V; Chen CC; Skeen JE; Sonenberg N; Hay N
J Biol Chem; 2005 Sep; 280(37):32081-9. PubMed ID: 16027121
[TBL] [Abstract][Full Text] [Related]
2. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.
Smith EM; Finn SG; Tee AR; Browne GJ; Proud CG
J Biol Chem; 2005 May; 280(19):18717-27. PubMed ID: 15772076
[TBL] [Abstract][Full Text] [Related]
3. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Lu KH; Wu W; Dave B; Slomovitz BM; Burke TW; Munsell MF; Broaddus RR; Walker CL
Clin Cancer Res; 2008 May; 14(9):2543-50. PubMed ID: 18451215
[TBL] [Abstract][Full Text] [Related]
4. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
5. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.
Inoki K; Li Y; Zhu T; Wu J; Guan KL
Nat Cell Biol; 2002 Sep; 4(9):648-57. PubMed ID: 12172553
[TBL] [Abstract][Full Text] [Related]
6. AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation.
Ning J; Clemmons DR
Mol Endocrinol; 2010 Jun; 24(6):1218-29. PubMed ID: 20363874
[TBL] [Abstract][Full Text] [Related]
7. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
[TBL] [Abstract][Full Text] [Related]
8. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism.
Yu S; Shen G; Khor TO; Kim JH; Kong AN
Mol Cancer Ther; 2008 Sep; 7(9):2609-20. PubMed ID: 18790744
[TBL] [Abstract][Full Text] [Related]
9. Follicle-stimulating hormone increases tuberin phosphorylation and mammalian target of rapamycin signaling through an extracellular signal-regulated kinase-dependent pathway in rat granulosa cells.
Kayampilly PP; Menon KM
Endocrinology; 2007 Aug; 148(8):3950-7. PubMed ID: 17510244
[TBL] [Abstract][Full Text] [Related]
10. Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR.
Dere R; Wilson PD; Sandford RN; Walker CL
PLoS One; 2010 Feb; 5(2):e9239. PubMed ID: 20169078
[TBL] [Abstract][Full Text] [Related]
11. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
Zhang H; Cicchetti G; Onda H; Koon HB; Asrican K; Bajraszewski N; Vazquez F; Carpenter CL; Kwiatkowski DJ
J Clin Invest; 2003 Oct; 112(8):1223-33. PubMed ID: 14561707
[TBL] [Abstract][Full Text] [Related]
12. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
14. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes.
Tremblay F; Gagnon A; Veilleux A; Sorisky A; Marette A
Endocrinology; 2005 Mar; 146(3):1328-37. PubMed ID: 15576463
[TBL] [Abstract][Full Text] [Related]
15. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation.
Ravitz MJ; Chen L; Lynch M; Schmidt EV
Cancer Res; 2007 Dec; 67(23):11209-17. PubMed ID: 18056446
[TBL] [Abstract][Full Text] [Related]
16. Selective activation of AMPK-PGC-1alpha or PKB-TSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation.
Atherton PJ; Babraj J; Smith K; Singh J; Rennie MJ; Wackerhage H
FASEB J; 2005 May; 19(7):786-8. PubMed ID: 15716393
[TBL] [Abstract][Full Text] [Related]
17. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression.
Buller CL; Loberg RD; Fan MH; Zhu Q; Park JL; Vesely E; Inoki K; Guan KL; Brosius FC
Am J Physiol Cell Physiol; 2008 Sep; 295(3):C836-43. PubMed ID: 18650261
[TBL] [Abstract][Full Text] [Related]
18. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.
Inoki K; Ouyang H; Zhu T; Lindvall C; Wang Y; Zhang X; Yang Q; Bennett C; Harada Y; Stankunas K; Wang CY; He X; MacDougald OA; You M; Williams BO; Guan KL
Cell; 2006 Sep; 126(5):955-68. PubMed ID: 16959574
[TBL] [Abstract][Full Text] [Related]
19. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
20. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance.
Khamzina L; Veilleux A; Bergeron S; Marette A
Endocrinology; 2005 Mar; 146(3):1473-81. PubMed ID: 15604215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
